c-LEcta Accelerates Distribution of DENARASE® and Signs Sales Agreement With VWR
c-LEcta, a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma, strengthens the product marketing of its patented nuclease enzyme DENARASE ® through a sales cooperation with VWR, a global trading company for laboratory supplies. DENARASE ® offers more efficient production processes for biopharmaceuticals and has market potential in the double-digit million-euro range.
To continue its growth strategy, c-LEcta is further expanding its track record in the commercialization of its products. In addition to the recent successes in the food sector, the company is now pushing the accelerated product marketing in the pharma industry. The German industrial biotechnology expert has signed an agreement with VWR, an international laboratory supplies trading company, to sell its DENARASE® product. The product, which was mainly marketed by c-LEcta itself, will make a significant contribution to the company's sales in the current fiscal year 2018. Through the cooperation with VWR, c-LEcta is now addressing customers in the life science sector in an even more targeted manner. VWR is an important source of raw materials for these customers.
DENARASE® is a nuclease enzyme. It helps to remove genetic information carriers (nucleic acids; DNA and RNA) from the production process of biopharmaceuticals. The complete removal of nucleic acids from biopharmaceutical products is necessary to meet the high regulatory requirements for these products. The production process of the enzyme is patented. DENARASE® is currently the most efficient technology on the market for removing nucleic acids. This considerably simplifies the production process, reduces follow-up costs to a competitive level and ensures reliable availability. The manufacturing process meets the highest quality requirements of cGMP (current Good Manufacturing Practice) and thus meets the high demands of pharmaceutical manufacturers.
In the pharmaceutical industry, DENARASE® is used in multiple areas. A large share currently falls on the established vaccine market. Here c-LEcta is already active as a supplier for pharmaceutical companies. Another field for DENARASE® is the development and fabrication of components for use in cell and gene therapy. According to estimates by c-LEcta, the marketing of DENARASE® has a worldwide market potential in the double-digit million-euro range.
CEO Marc Struhalla: "With DENARASE®, we enable higher efficiencies in production processes than in conventional approaches and also set new standards in quality. In terms of price/performance ratio, we are thus offering the pharmaceutical industry a very attractive offer for optimizing their manufacturing procedures. The combination of our product innovation and VWR's access to the life science sector gives us the best prerequisites for gaining additional market share in a very dynamic market. We expect additional sales in the millions as an important contribution to our strong growth."
About c-LEcta
c-LEcta is a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma. The company is located in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry partners. The company currently employs approximately 60 people.
c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181009005155/en/
Contact information
cometis AG for c-LEcta
Maximilian Franz
Phone: +49 (0)
611 - 205855 – 22
Fax: +49 (0) 611 - 205855 – 66
E-mail: franz@cometis.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions9.12.2025 17:47:00 EET | Press release
Rapid Medical™, a leading developer of active endovascular devices, announces the completion of patient enrollment in the DISTALS Trial, a multicenter randomized study assessing the TIGERTRIEVER 13™ device in patients with distal medium vessel occlusions (DMVO) in acute ischemic stroke. “DMVO strokes represent up to 40% of ischemic strokes and can cause significant disability, yet their treatment has remained uncertain. Recent neutral results from ESCAPE-MEVO and DISTAL made one thing clear: distal thrombectomy requires devices and trials specifically engineered for distal vessels,” said Dr. Jeffrey Saver of UCLA in California, Principal Investigator of DISTALS. “TIGER 13 and DISTALS bring that dedicated design. Completing enrollment is a major step toward evidence that can truly advance care for these patients.” The TIGER 13 is purpose-built for distal interventions. Its proprietary adjustable design is the only thrombectomy device that can actively remove tension from the vessel duri
Suzano Launches Nature Strategy and Reinforces the Strategic Importance of Biodiversity Conservation to the Business9.12.2025 17:41:00 EET | Press release
Suzano, the world’s largest pulp producer, has launched its Nature Strategy, reaffirming the company's commitment to biodiversity and how it guides decision-making within the business. Suzano's operations depend directly on nature, and the company recognizes that its longevity and ability to innovate are intrinsically linked to the health of ecosystems. Therefore, nature occupies a significant strategic role in the business’ vision. The science-led Nature Strategy, developed in collaboration with IUCN, is guided by the mitigation hierarchy: avoid, reduce, restore and transform. This approach enables the prevention of impacts, the minimization of risks, and the promotion of ecosystem regeneration. With support from IUCN, Suzano has pioneered the use of the STAR metric – a tool that enables the company to map sensitive areas within the territories where it operates, identify endangered species, and set priority actions required to reduce their risk of extinction. Biodiversity monitoring
Winners of the Global Prize for Innovation in Water Announced9.12.2025 17:28:00 EET | Press release
The city of Jeddah today witnessed a landmark global event with the announcement of the winners of the Global Prize for Innovation in Water in its third edition, marking the conclusion of a highly competitive showcase that drew the attention of the international water community. The winners were revealed during the opening ceremony held as part of the fourth edition of the Innovation Driven Water Sustainability Conference (IDWS2025). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209514013/en/ Winners of the Global Prize for Innovation in Water Announced (Photo: AETOSWire) During the ceremony, the names of 14 winners were announced. Their pioneering solutions succeeded in meeting the rigorous criteria set by the international jury panel. With total prizes amounting to 10 million dollars across all stages, the award recognizes exceptional efforts in transforming research ideas into practical, real-world water technologies.
ITA Group Expands Global Event Capabilities With Two European Acquisitions9.12.2025 17:00:00 EET | Press release
ITA Group, a global leader in engagement solutions, is announcing the strategic acquisition of two award-winning European event agencies: C2events, based in West Yorkshire, England, and Daymakers, based in Utrecht, Netherlands. Effective October 31, 2025, these acquisitions significantly expand ITA Group's local presence and event capabilities throughout Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209885574/en/ Back row: Mark Saxby – C2, Executive Director, Brent Vander Waal – ITA Group, CEO; Front row: Sarah Haines – ITA Group, President Event Solutions, Sophie Hopes – C2, Client Services Director, Danielle Gunn – C2, Client Services Director, Cheryl Clarke – C2, Executive Director, Erica Lalk – ITA Group, Director - Global & Event Strategy The dual acquisitions strengthen ITA Group's position as a global events leader, offering current and prospective clients immediate benefits, including: In-region event tea
Andersen Global Strengthens Valuation Capabilities in Asia Pacific with ETC9.12.2025 16:30:00 EET | Press release
Andersen Global continues to expand its presence in Asia Pacific through a Collaboration Agreement with Edmund Tie & Company (ETC), a full-service real estate advisory firm headquartered in Singapore. Established in 1995, ETC delivers valuation and advisory services across the real estate lifecycle, including statutory and corporate valuation, investment advisory, feasibility studies, and property tax advisory. Operating across Singapore, Malaysia, and Thailand, ETC combines deep regional knowledge with international standards to support developers, investors, private and sovereign funds, corporations, REITs, and owners and occupiers. Known for its research-driven approach and integrated service model, the firm helps clients navigate regulatory complexity and optimize asset value. “Our strength lies not just in technical execution, but in helping clients see the full picture—connecting market signals, regulatory shifts, and long-term value drivers,” said Desmond Sim, CEO of ETC. “Colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom